Sepsis is a common and deadly side-effect of a bloodstream infection. Millions of people are diagnosed with sepsis each year, and on average 30% of them will succumb to the severe inflammation and coagulation abnormalities that result. CNM scientists have discovered a receptor system in the body that modulates sepsis. This receptor system controls blood coagulation and thrombosis thereby promoting host survival of pneumococcal sepsis. We have further learned how to manipulate this receptor system to reduce inflammation and increase survival in both Gram-positive and Gram-negative sepsis. There have not been any effective drugs developed to treat sepsis for decades, and the pharmaceutical industry has mostly dropped all sepsis research and development programs. CNM discoveries of a novel receptor system in the body that modulates sepsis by controlling blood protein aging and turnover has provided a new class of molecules for targeted therapies for sepsis. CNM scientists are working to establish this potential and in collaboration with our colleagues at Cottage Hospital we are analyzing hundreds of sepsis patients to identify the most precise means by which to treat sepsis and increase patient survival of this deadly syndrome.